Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectors

Abstract

Previous reports have suggested that bone morphogenetic protein (BMP) gene therapy could be applied for in vivo bone regeneration. However, these studies were conducted either using immunodeficient animals because of immunogenicity of adenovirus vectors, or using ex vivo gene transfer technique, which is much more difficult to handle. Adeno-associated virus (AAV) is a replication-defective virus without any association with immunogenicity and human disease. This study was conducted to investigate whether orthotopic new bone formation could be induced by in vivo gene therapy using AAV-based BMP2 vectors. To test the feasibility of this approach, we constructed an AAV vector carrying human BMP2 gene. Mouse myoblast cells (C2C12) transduced with this vector could produce and secrete biologically active BMP2 protein and induce osteogenic activity, which was confirmed by ELISA and alkaline phosphatase activity assay. For in vivo study, AAV-BMP2 vectors were directly injected into the hindlimb muscle of immunocompetent Sprague–Dawley rats. Significant new bone under X-ray films could be detected as early as 3 weeks postinjection. The ossification tissue was further examined by histological and immunohistochemical analysis. This study is, to our knowledge, the first to establish the feasibility of AAV-based BMP2 gene therapy for endochondral ossification in immunocompetent animals.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Wozney JM, Rosen V . Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop 1998; 346: 26–37.

    Article  Google Scholar 

  2. Chen Y . Orthopaedic applications of gene therapy. J Orthop Sci 2001; 6: 199–207.

    Article  CAS  PubMed  Google Scholar 

  3. Sandhu JS et al. Effect of interleukin-6 secreted by engineered human stromal cells on osteoclasts in human bone. Bone 1999; 24: 217–227.

    Article  CAS  PubMed  Google Scholar 

  4. Breitbart AS et al. Gene-enhanced tissue engineering: applications for bone healing using cultured periosteal cells transduced retrovirally with the BMP-7 gene. Ann Plast Surg 1999; 42: 488–495.

    Article  CAS  PubMed  Google Scholar 

  5. Engstrand T et al. Transient production of bone morphogenetic protein 2 by allogeneic transplanted transduced cells induces bone formation. Hum Gene Ther 2000; 11: 205–211.

    Article  CAS  PubMed  Google Scholar 

  6. Alden TD et al. In vivo endochondral bone formation using a bone morphogenetic protein-2 adenoviral vector. Hum Gene Ther 1999; 10: 2245–2253.

    Article  CAS  PubMed  Google Scholar 

  7. Franceschi RT, Wang D, Krebsbach PH, Rutherford RB . Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Chem 2000; 78: 476–486.

    CAS  Google Scholar 

  8. Lieberman JR et al. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg 1999; 81A: 905–917.

    Article  Google Scholar 

  9. Chen Y et al. In vivo new bone formation by direct transfer of adenoviral mediated bone morphogenetic protein-4 gene. Biochem Biophys Res Commun 2002; 298: 121–127.

    Article  CAS  PubMed  Google Scholar 

  10. Jiang ZL et al. Local high-capacity adenovirus-mediated mCTLA4Ig and mCD40Ig expression prolongs recombinant gene expression in skeletal muscle. Mol Ther 2001; 3: 892–900.

    Article  CAS  PubMed  Google Scholar 

  11. Monahan PE, Samulski RJ . Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000; 6: 433–440.

    Article  CAS  PubMed  Google Scholar 

  12. Rabinowitz JE, Samulski J . Adeno-associated virus expression systems for gene transfer. Curr Opin Biotechnol 1998; 9: 470–475.

    Article  CAS  PubMed  Google Scholar 

  13. Muzyczka N . Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992; 158: 97–129.

    CAS  PubMed  Google Scholar 

  14. Samulski RJ, Chang LS, Shenk T . Helper-free stocks of recombinant adeno-associated viruses: nor malintegration does not require viral gene expression. J Virol 1989; 63: 3822–3828.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Xiao X, Li J, Samulski RJ . Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098–8108.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Katagiri T et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 1994; 127: 1755–1766.

    Article  CAS  PubMed  Google Scholar 

  17. Wilson JM . Adenovirus as gene-delivery vehicles. N Engl J Med 1996; 334: 1185–1187.

    Article  CAS  PubMed  Google Scholar 

  18. Apparailly F et al. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum Gene Ther 2002; 13: 1179–1188.

    Article  CAS  PubMed  Google Scholar 

  19. Grimm D, Kern A, Rittner K, Kleinschmidt JA . Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 1998; 9: 2745–2760.

    Article  CAS  PubMed  Google Scholar 

  20. Auricchio A et al. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 2001; 12: 71–76.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Laboratory Animal Unit, The University of Hong Kong for helping us with animal holding and maintenance. Also, we are grateful to Mr David Wilmshurst, the technical writer in The University of Hong Kong, for his kind review on this manuscript. This study was supported by a University Research Grant (2000–2001) from The University of Hong Kong.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, Y., Luk, K., Cheung, K. et al. Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectors. Gene Ther 10, 1345–1353 (2003). https://doi.org/10.1038/sj.gt.3301999

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301999

Keywords

This article is cited by

Search

Quick links